Influency of pentoxifylline treatment for neonatal sepsis: A meta-analysis of randomized controlled studies

Abstract

Introduction:

Pentoxifylline may be an important approach to treat neonatal sepsis. However, its use has not been well established. We conduct a systematic review and meta-analysis to evaluate the efficacy of pentoxifylline treatment for neonatal sepsis.

Methods:

PubMed, Embase, and the Cochrane Central Register of Controlled Trials are searched. Randomized controlled trials assessing the influence of pentoxifylline treatment on neonatal sepsis are included. Two investigators independently have searched articles, extracted data, and assessed the quality of included studies. This meta-analysis is performed using the random-effect model.

Results:

Seven randomized controlled trials involving 439 patients are included in the meta-analysis. Compared with control intervention for neonatal sepsis, pentoxifylline treatment is associated with reduced hospital stay (standard mean differences = −0.61; 95% confidence interval = −0.93 to −0.29; p = 0.0002) and metabolic acidosis (risk ratio = 0.38; 95% confidence interval = 0.22 to 0.66; p = 0.0006), but has no remarkable impact on mortality (risk ratio = 0.59; 95% confidence interval = 0.30 to 1.16; p = 0.13), serum tumor necrosis factor-α (standard mean differences = −0.38; 95% confidence interval = −1.29 to 0.52; p = 0.41), serum C-reactive protein (standard mean differences = −0.25; 95% confidence interval = −0.92 to 0.42; p = 0.47), plasma interleukin-6 (standard mean differences = −0.13; 95% confidence interval = −0.41 to 0.15; p = 0.37), disseminated intravascular coagulopathy (risk ratio = 0.55; 95% confidence interval = 0.25 to 1.21; p = 0.14), and oliguria/anuria (risk ratio = 0.77; 95% confidence interval = 0.28 to 2.16; p = 0.62).

Conclusion:

Pentoxifylline treatment may be associated with reduced mortality and hospital stay in neonatal sepsis with caution.

Keywords

Pentoxifylline neonatal sepsis mortality randomized controlled trials meta-analysis

Introduction

Neonatal sepsis is known as the most common cause of death in newborn infants, with the incidence of 6.5–38 among 1000 live births.^1–3 The combined rate of major morbidity and mortality of sepsis is up to 10%–20% for all infants and 20%–30% for very low-birth-weight infants.^4–6 Preterm infants with Gram-negative septic shock have the death rate of 65%–85% despite of broad-spectrum antibiotics and intensive supporting care.⁷ The morbidity and mortality may be caused by ineffective antibiotics to multidrug-resistant bacteria or a weak host defense mechanisms in preterm infants.^8–10

Adjuvant therapies may be increasingly important to increase the efficacy of antimicrobial agents and overcome excessive or uncontrolled inflammatory response in sepsis.^11–13 Redox-active agents (e.g. lactoferrin, zinc, selenium, ibuprofen, edaravone, and pentoxifylline) have shown some efficacy to treat neonatal sepsis.^14–17 Pentoxifylline is a phosphodiesterase inhibitor among other actions and can inhibit the production of tumor necrosis factor-alpha (TNF-α), preserve microvascular blood flow, prevent circulatory failure and intestinal vasoconstriction. It is reported to have beneficial effects on endothelial cell function and coagulation in sepsis and the reduction of mortality from sepsis.^18–20

However, the use of pentoxifylline for neonatal sepsis has not been well established. Recently, several studies on the topic have been published, and the results have been conflicting.^21–24 Considering these inconsistent effects, we therefore conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) to evaluate the efficacy of pentoxifylline treatment for neonatal sepsis.

Materials and methods

Ethical approval and patient consent are not required since this is a systematic review and meta-analysis of previously published studies. The systematic review and meta-analysis are conducted and reported in adherence to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses).²⁵

Search strategy and study selection

Two investigators have independently searched the following databases (inception to June 2018): PubMed, Embase, and the Cochrane Register of Controlled Trials. The electronic search strategy is performed using the following keywords: pentoxifylline, neonatal or infants or neonate, and sepsis. We also have checked the reference lists of the screened full-text studies to identify other potentially eligible trials.

The following inclusive selection criteria are applied: (1) population: neonatal sepsis, (2) intervention: pentoxifylline treatment, (3) comparison: matched placebo, and (4) study design: RCT.

Data extraction and outcome measures

We have used a piloted data-extraction sheet, which covers the following information: first author, number of patients, gestational age, male, birth weight, and detail methods in two groups. Data are extracted independently by two investigators, and discrepancies are resolved by consensus. We have contacted the corresponding author to obtain the data when necessary. No simplifications and assumptions are made.

The primary outcome is mortality. Secondary outcomes include hospital stay, serum TNF-α, serum C-reactive protein (CRP), plasma interleukin (IL)-6, metabolic acidosis, disseminated intravascular coagulopathy, and oliguria/anuria.

Quality assessment in individual studies

The Jadad Scale is used to evaluate the methodological quality of each RCT included in this meta-analysis.²⁶ This scale consists of three evaluation elements: randomization (0–2 points), blinding (0–2 points), and dropouts and withdrawals (0–1 points). One point would be allocated to each element if they have been mentioned in article, and another one point would be given if the methods of randomization and/or blinding had been appropriately described. If the methods of randomization and/or blinding were inappropriate, or dropouts and withdrawals had not been recorded, then one point was deducted. The score of Jadad Scale varies from 0 to 5 points. An article with Jadad score ⩽2 is considered to be of low quality. If the Jadad score ⩾3, the study is thought to be of high quality.²⁷

Statistical analysis

We have estimated standard mean differences (Std. MDs) with 95% confidence intervals (CIs) for continuous outcomes (hospital stay, serum TNF-α, serum CRP, and plasma IL-6) and risk ratios (RRs) with 95% CIs for dichotomous outcomes (mortality, metabolic acidosis, disseminated intravascular coagulopathy, and oliguria/anuria). A random-effects model is used regardless of heterogeneity. Heterogeneity is reported using the I² statistic, and I² > 50% indicates significant heterogeneity.²⁸ Whenever significant heterogeneity is present, we search for potential sources of heterogeneity. Sensitivity analysis is performed to detect the influence of a single study on the overall estimate via omitting one study in turn when necessary. Owing to the limited number (<10) of included studies, publication bias is not assessed. Results are considered as statistically significant for P < 0.05. All statistical analyses are performed using Review Manager Version 5.3 (The Cochrane Collaboration, Software Update, Oxford, UK).

Results

Literature search, study characteristics, and quality assessment

A detailed flowchart of the search and selection results is shown in Figure 1; 719 potentially relevant articles are identified initially. Finally, seven RCTs that meet our inclusion criteria are included in the meta-analysis.^{20–24,29,30}

Figure 1.

Flow diagram of study searching and selection process.

The main characteristics of the seven included RCTs are presented in Table 1. The seven studies are published between 1996 and 2015, and sample sizes range from 20 to 120 with a total of 439. Pentoxifylline is administered by 5–6 mg/kg/h intravenously for 4–6 h daily, and the duration time ranges from 3 days to 6 days.

Table 1.

Characteristics of included studies.

No.	Author	Pentoxifylline group					Control group					Jada scores
No.	Author	Number	Gestational age (weeks)	Male (n)	Birth weight (g)	Methods	Number	Gestational age (weeks)	Male (n)	Birth weight (g)	Methods
1	Shabaan et al.²¹	60	30.2 ± 2.5	34	1404 ± 417	Intravenous pentoxifylline 5 mg/kg/h for 6 h on six successive days	60	30.1 ± 2.2	44	1370 ± 471	Matched placebo	5
2	Akdag et al.²²	51	31 (24–42)	29	1490 (620–4580)	Pentoxifylline 6 mg/kg/h intravenously, over 4 h, daily for three consecutive days	51	31 (25–40)	33	1,410 (620–4300)	Matched placebo	4
3	Adel et al.²³	17	35.94 ± 4.04	9	2470 ± 890	Pentoxifylline 5 mg⁄kg⁄h for 6 h, for six successive days	20	36.05 ± 3.2	11	2210 ± 590	Matched placebo	4
4	Ali et al.²⁴	25	32–37	–	950–2580	Pentoxifylline 5 mg/kg/h for 6 h, for three successive days	25	32–37	–	1000–2650	Matched placebo	3
5	Selim et al.²⁹	13	37.62 ± 2.43	–	2509 ± 549	Initially 0.5 h before beginning antibiotic therapy and given in a dose of 0.5 mg/kg/h by continuous infusion for 24 h	7	38 ± 2.08	–	2822 ± 637	Matched placebo
6	Lauterbach et al.³⁰	40	31.6 ± 2.9	23	1690.2 ± 396.5	Pentoxifylline 5 mg⁄kg⁄h for 6 h, for 6 successive days	38	32.8 ± 3.01	20	1749.8 ± 475.6	Matched placebo
7	Lauterbach and Zembala²⁰	16	31.54 ± 31	–	1752.09 ± 483.4	Pentoxifylline 5 mg⁄kg⁄h for 6 h, for three successive days	16	32.35 ± 33	–	1861.29 ± 511.7	Matched placebo

Among the seven RCTs, six studies have reported mortality,^20–24,30 two studies have reported hospital stay,^21,23 three studies have reported serum TNF-α and serum CRP,^21,22,29 three studies have reported plasma IL-6,^22,29,30 two studies have reported metabolic acidosis,^21,30 four studies have reported disseminated intravascular coagulopathy,^21–23,30 and four studies have reported oliguria/anuria.^21–23,30 Jadad scores of the seven included studies vary from 3 to 5, and all seven studies are considered to be high-quality ones according to quality assessment.

Primary outcome: mortality

These outcome data are analyzed with the random-effects model, and the pooled estimate of the six included RCTs suggested that compared to control group for neonatal sepsis, pentoxifylline treatment has no significant influence on mortality (RR = 0.59; 95% confidence interval (CI) = 0.30 to 1.16; p = 0.13), with low heterogeneity among the studies (I² = 30%, heterogeneity p = 0.21, Figure 2).

Figure 2.

Forest plot for the meta-analysis of mortality.

Sensitivity analysis

Low heterogeneity is observed among the included studies for the primary outcome. As shown in Figure 2, the study conducted by Akdag et al.²² shows the results that are almost out of range of the others and probably contribute to the heterogeneity. After excluding this study, the results suggests that pentoxifylline treatment can significantly reduce mortality (RR = 0.50; 95% CI = 0.29 to 0.88; p = 0.02), and there is no heterogeneity among the remaining RCTs (I² = 0%, heterogeneity p = 0.44, Figure 3).

Figure 3.

Forest plot for the meta-analysis of mortality for sensitivity analysis.

Secondary outcomes

Compared to control group for neonatal sepsis, pentoxifylline treatment is associated with remarkably decreased hospital stay (Std. MD = −0.61; 95% CI = −0.93 to −0.29; p = 0.0002; Figure 4), but shows no significant impact on serum TNF-α (Std. MD = −0.38; 95% CI = −1.29 to 0.52; p = 0.41; Figure 5), serum CRP (Std. MD = −0.25; 95% CI = −0.92 to 0.42; p = 0.47; Figure 6), plasma IL-6 (Std. MD = −0.13; 95% CI = −0.41 to 0.15; p = 0.37; Figure 7). In addition, metabolic acidosis in pentoxifylline group is lower than that in control group (RR = 0.38; 95% CI = 0.22 to 0.66; p = 0.0006; Figure 8). There is no significant difference of disseminated intravascular coagulopathy (RR = 0.55; 95% CI = 0.25 to 1.21; p = 0.14; Figure 9) and oliguria/anuria (RR = 0.77; 95% CI = 0.28 to 2.16; p = 0.62; Figure 10) between two groups.

Figure 4.

Forest plot for the meta-analysis of hospital stay (days).

Figure 5.

Forest plot for the meta-analysis of serum TNF-α.

Figure 6.

Forest plot for the meta-analysis of serum CRP.

Figure 7.

Forest plot for the meta-analysis of plasma IL-6.

Figure 8.

Forest plot for the meta-analysis of metabolic acidosis.

Figure 9.

Forest plot for the meta-analysis of disseminated intravascular coagulopathy.

Figure 10.

Forest plot for the meta-analysis of oliguria/anuria.

Discussion

Strong and expensive antimicrobials agents have been extensively developed, but the mortality and morbidity of infants with sepsis are still high.^21,31,32 Adjuvant therapies using pentoxifylline have gained the great interest in clinical work.¹⁴ Pentoxifylline is a nonsteroidal immunomodulating agent with unique hemorrheologic effects and has been used in kinds of infectious, vascular, and inflammatory diseases in children because of its potent anti-inflammatory properties through downregulation of proinflammatory cytokines and blood viscosity and the increase in microcirculation and tissue perfusion.^22,29 The current evidence is weakened, and the routine use of pentoxifylline in neonatal sepsis has not been recommended.

One RCT has reported that pentoxifylline has no influence on mortality in preterm infants with suspected or confirmed sepsis.²¹ In contrast, significant reduction of mortality is observed in infants receiving pentoxifylline in other studies.^24,30 One recent Cochrane review includes six small RCTs and quasi-RCTs and reveals a significant reduction in all-cause mortality during hospital stay in neonates with sepsis after the use of pentoxifylline as an adjunct to antibiotics.³³ Our meta-analysis has included seven RCTs involving 439 neonates, and the results demonstrate that pentoxifylline has no substantial impact on mortality for neonatal sepsis, but is associated with significantly reduced hospital stay.

TNF-α, IL-1, and IL-6 concentrations can be elevated in preterm infants with sepsis, and their high concentrations of those cytokines are associated with high mortality.³⁴ TNF-α, CRP, and IL-6 do not differ between pentoxifylline group and control group based on the results of our meta-analysis. In addition, pentoxifylline treatment is associated with significantly reduced metabolic acidosis, but with no impact on disseminated intravascular coagulopathy and oliguria/anuria. Regarding the sensitivity analysis, significant reduction of mortality is found in pentoxifylline group compared to that in control group after excluding the study conducted by Akdag et al.²² (RR = 0.50; 95% CI = 0.29 to 0.88; p = 0.02), and there is no heterogeneity among the remaining RCTs. That study reports 24 mg/kg pentoxifylline daily, and other included RCTs report 30 mg/kg pentoxifylline daily. This heterogeneity may be attributed to the dose of pentoxifylline use daily. In addition, the differences in mortality are possibly caused by different organisms of neonatal sepsis.²²

This meta-analysis has several potential limitations that should be taken into account. First, our analysis is based on only seven RCTs, and five of them have a small sample size (n < 100). Overestimation of the treatment effect is more likely in smaller trials compared with larger samples. Next, the heterogeneity of mortality in this meta-analysis is possibly caused by different doses and methods of pentoxifylline treatment. Finally, some unpublished and missing data may lead bias to the pooled effect.

Conclusion

Pentoxifylline treatment may provide some benefits to neonates with sepsis with caution.

Footnotes

Author contributions

All authors read and approved the final manuscript.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iD

Yunfeng Xia

References

Lawn

Wilczynska-Ketende

Cousens

SN.

Estimating the causes of 4 million neonatal deaths in the year 2000. Int J Epidemiol 2006; 35(3): 706–718.

Zaidi

Huskins

Thaver

, et al. Hospital-acquired neonatal infections in developing countries. Lancet 2005; 365(9465): 1175–1188.

Zea-Vera

Ochoa

TJ.

Challenges in the diagnosis and management of neonatal sepsis. J Trop Pediatr 2015; 61(1): 1–13.

Talbert

Mwaniki

Mwarumba

, et al. Invasive bacterial infections in neonates and young infants born outside hospital admitted to a rural hospital in Kenya. Pediatr Infect Dis J 2010; 29(10): 945–949.

Bader

Kugelman

Boyko

, et al. Risk factors and estimation tool for death among extremely premature infants: a national study. Pediatrics 2010; 125(4): 696–703.

Shah

Padbury

JF.

Neonatal sepsis: an old problem with new insights. Virulence 2014; 5(1): 170–178.

Baley

JE.

Neonatal sepsis: the potential for immunotherapy. Clin Perinatol 1988; 15(4): 755–771.

Wynn

Cornell

Wong

, et al. The host response to sepsis and developmental impact. Pediatrics 2010; 125(5): 1031–1041.

Bandyopadhyay

Kumar

Saili

, et al. Distribution, antimicrobial resistance and predictors of mortality in neonatal sepsis. J Neonatal Perinatal Med 2018; 11(2): 145–153.

10.

Pokhrel

Koirala

Shah

, et al. Bacteriological profile and antibiotic susceptibility of neonatal sepsis in neonatal intensive care unit of a tertiary hospital in Nepal. BMC Pediatr 2018; 18(1): 208.

11.

Wong

, et al. Proinflammatory and anti-inflammatory cytokine responses in preterm infants with systemic infections. Arch Dis Child Fetal Neonatal Ed 2003; 88(3): F209–F213.

12.

Hamilcikan

Can

Buke

, et al. Pentoxifylline and Pentaglobin adjuvant therapies for neonatal nosocomial sepsis in neonates less than 1500g weight. J Pak Med Assoc 2017; 67(10): 1482–1486.

13.

ElFrargy

El-Sharkawy

Attia

GF.

Use of melatonin as an adjuvant therapy in neonatal sepsis. J Neonatal Perinatal Med 2015; 8(3): 227–232.

14.

Bajcetic

Spasic

Spasojevic

Redox therapy in neonatal sepsis: reasons, targets, strategy, and agents. Shock 2014; 42(3): 179–184.

15.

Garg

Bansal

Kabra

NS.

Role of selenium supplementation in prevention of late onset sepsis among very low birth weight neonates: a systematic review of randomized controlled trials. J Matern Fetal Neonatal Med. Epub ahead of print 20 June 2018. DOI: 10.1080/14767058.2018.1481039.

16.

Tang

Wei

Wen

, et al. Efficacy of zinc supplementation for neonatal sepsis: a systematic review and meta-analysis. J Matern Fetal Neonatal Med. Epub ahead of print 12 December 2017. DOI: 10.1080/14767058.2017.1402001.

17.

Yamaguchi

Hussein

Daoud

, et al. Edaravone, a hydroxyl radical scavenger, ameliorates the severity of pulmonary hypertension in a porcine model of neonatal sepsis. Tohoku J Exp Med 2011; 223(4): 235–241.

18.

Harris

Schulzke

Patole

SK.

Pentoxifylline in preterm neonates: a systematic review. Paediatr Drugs 2010; 12(5): 301–311.

19.

Vilcek

Lee

TH.

Tumor necrosis factor. New insights into the molecular mechanisms of its multiple actions. J Biol Chem 1991; 266(12): 7313–7316.

20.

Lauterbach

Zembala

Pentoxifylline reduces plasma tumour necrosis factor-alpha concentration in premature infants with sepsis. Eur J Pediatr 1996; 155(5): 404–409.

21.

Shabaan

Nasef

Shouman

, et al. Pentoxifylline therapy for late-onset sepsis in preterm infants: a randomized controlled trial. Pediatr Infect Dis J 2015; 34(6): e143–e148.

22.

Akdag

Dilmen

Haque

, et al. Role of pentoxifylline and/or IgM-enriched intravenous immunoglobulin in the management of neonatal sepsis. Am J Perinatol 2014; 31: 905–912.

23.

Adel

Awad

Abdel-Naim

, et al. Effects of pentoxifylline on coagulation profile and disseminated intravascular coagulation incidence in Egyptian septic neonates. J Clin Pharm Ther 2010; 35(3): 257–265.

24.

Ali

Ahmed

Bhat

, et al. Pentoxifylline in treatment of sepsis of premature infants. JK-Practitioner 2006; 13: 204–207.

25.

Moher

Liberati

Tetzlaff

, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009; 339: b2535.

26.

Jadad

Moore

Carroll

, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 1996; 17(1): 1–12.

27.

Kjaergard

Villumsen

Gluud

Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med 2001; 135: 982–989.

28.

Higgins

Thompson

SG.

Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539–1558.

29.

Selim

Huseyin

Ibrahim

, et al. Effect of pentoxifylline on tumor necrosis factor-alpha and interleukin-6 levels in neonatal sepsis. Med J Malaysia 2004; 59(3): 391–394.

30.

Lauterbach

Pawlik

Kowalczyk

, et al. Effect of the immunomodulating agent, pentoxifylline, in the treatment of sepsis in prematurely delivered infants: a placebo-controlled, double-blind trial. Crit Care Med 1999; 27(4): 807–814.

31.

Nunes

Xavier

Martins

RR.

Antimicrobial drug-related problems in a neonatal intensive care unit. Rev Bras Ter Intensiva 2017; 29(3): 331–336.

32.

Gandra

Alvarez-Uria

Murki

, et al. Point prevalence surveys of antimicrobial use among eight neonatal intensive care units in India: 2016. Int J Infect Dis 2018; 71: 20–24.

33.

Pammi

Haque

KN.

Pentoxifylline for treatment of sepsis and necrotizing enterocolitis in neonates. Cochrane Database Syst Rev 2015; 3: CD004205.

34.

de Bont

Martens

van Raan

, et al. Tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6 plasma levels in neonatal sepsis. Pediatr Res 1993; 33(4 Pt. 1): 380–383.